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Abstract
Objectives: Elevated cortisol in stress and aging, such as has been seen in late-life anxiety
disorders, is postulated to accelerate cognitive and physiological decline in this large and
increasing population. Selective serotonin-reuptake inhibitors (SSRIs) and cognitive behavior
therapy (CBT) are both effective treatments for Generalized Anxiety Disorder (GAD) in older
adults. On the other hand, there is very little research examining the effect of combining these
therapies on peak cortisol levels. For the current analyses, we examined the effectiveness of
CBT augmentation on peak cortisol levels in older adults diagnosed with GAD.
Methods: The sample consisted of 42 individuals with late-life GAD who received an acute
course of the SSRI escitalopram and then entered a 16-week randomized phase. Twenty-one
participants were randomized to receive 16 sessions of CBT in addition to continuing
escitalopram and the remaining 21 participants continued on escitalopram without CBT.
Generalized Estimating Equations were performed to assess the effectiveness of CBT
augmentation on peak cortisol levels (30 minutes after waking).
Results: Older adults with GAD who received both escitalopram and CBT demonstrated a
significant reduction in peak cortisol levels at post-treatment compared to the group who
received escitalopram without CBT augmentation.
Conclusions: CBT augmentation of SSRI treatment reduced peak cortisol levels for older adults
with GAD. Since persistently high cortisol levels in aging are thought to increase age-related
cognitive and medical problems, our findings suggest that there may be a benefit to health and
cognition of CBT augmentation for late-life anxiety disorders.
KEYWORDS: Generalized anxiety disorder (GAD); HPA axis; escitalopram; cognitive
behavioral therapy (CBT); cortisol
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Cognitive-Behavioral Therapy Augmentation of SSRI Reduces Cortisol Levels in Older Adults
with Generalized Anxiety Disorder: A Randomized Clinical Trial

The prevalence of anxiety disorders is high in the older adult population (see WolitzkyTaylor, Castriotta, Lenze, Stanley, & Craske, 2010). More specifically, prevalence estimates of
Generalized Anxiety Disorder (GAD) in older adults range from 1.2 to 7% (Angst, Gamma,
Baldwin, Ajdacic-Gross, & Rossler, 2009; Beekman et al., 1998; Goncalves & Byrne, 2012a;
Gum, King-Kallimanis, & Kohn, 2009; Grant et al., 2005) with a peak age of onset around 40-50
years of age (Goncalves & Byrne, 2012a). Further, the prevalence of GAD appears to increase
until 50-60 years of age (Ansseau, Fischler, Dierick, Mignon, & Leyman, 2005; Carter,
Wittchen, Pfister, & Kessler, 2001). Importantly, the diagnosis of GAD is related to several
negative outcomes including an increased likelihood of being diagnosed with other comorbid
disorders (e.g., major depressive disorder; Byers, Yaffe, Covinsky, Friedman, & Bruce, 2010;
Carter et al., 2001), higher rates of disability (Ansseau et al, 2005; Romera et al., 2010), lower
levels of health related quality of life (Wetherell et al., 2004), greater healthcare utilization
(Porensky et al., 2009) and poorer cognitive performance (Butters et al., 2011; Mantella et al.,
2007; Rosnick, Rawson, Butters, & Lenze, 2013) which has been reported to be related to poorer
treatment outcomes (Caudle et al., 2007).
There are effective pharmacological and psychotherapeutic techniques for older adults
with GAD (see Goncalves & Byrne, 2012b for review and meta-analysis). For instance, studies
have shown that cognitive behavioral therapy (CBT) reduces levels of worry, anxiety, depressive
symptoms (Gould, Coulson, & Howard, 2012; Stanley et al., 2003; Stanley et al., 2009) and
increases self-reported quality of life in older adults with GAD relative to waiting list (Ayers,
Sorrell, Thorp, & Wetherell, 2007; Mitte, 2005) but these changes may not be superior to other
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comparison interventions (Wetherell, Gatz, & Craske, 2003). For example, relaxation training
(RT) has also been reported as having a large positive effect in treating geriatric anxiety (Thorp
et al., 2009).
Medication is frequently used to treat older adults with GAD. Serotonergic
antidepressant medications such as venlafaxine ER (Katz, Reynolds, Alexopoulos, & Hackett,
2002) and SSRIs such as escitalopram (Lenze et al., 2009), citalopram (Lenze et al., 2005), and
sertraline (Schuurmans et al., 2006) have been shown to be effective pharmacological treatments
for older adults with GAD. It has been suggested, however, that SSRI monotherapy is not
typically sufficient to achieve full remission of GAD for most older adults (Lenze et al., 2009;
see also Pinquart & Duberstein, 2007), providing a rationale for augmentation with behavioral
therapies.
Older adults with anxiety disorders are more reactive to stressors (Chaudieu et al., 2008;
Vasiliadis, Forget, & Preville, 2013) and exhibit elevated cortisol levels compared to healthy
older adults (Mantella et al., 2008). This is important because chronically high cortisol in older
adults is thought to lead to the deleterious health and cognitive effects of stress (Lenze &
Wetherell, 2011). Effective cortisol reduction may therefore be an important dimension of
treatments’ benefits in this age group. Cognitive behavioral interventions have been shown to be
effective in reducing cortisol levels in younger and middle-aged adults with other anxiety
disorders (e.g., protective mask phobia: Brand, Annen, Holsboer-Trachsler, & Blaser, 2011).
More specifically, Tafet, Feder, Abulafia, and Roffman (2005) reported that non-elderly
individuals with GAD who underwent 24 weeks of cognitive therapy demonstrated a significant
reduction in afternoon cortisol levels but no significant differences were found in morning
cortisol levels compared to a control group. Additionally, Lenze and colleagues (2011) reported

ESCITALOPRAM AND CBT AUGMENTATION

5

that escitalopram treatment for late-life GAD reduced peak (i.e., 30 minutes after waking) and
total cortisol levels, and that treatment-attributable reduction in peak cortisol levels correlated
with improvement in memory (Lenze et al., 2012).
The authors know of no research to date that has examined the effect of psychotherapy on
cortisol levels in older adults with an anxiety disorder, either alone or in combination with
medication. Recently, Wetherell and colleagues (2013) showed that SSRI medication
augmented with CBT led to greater reduction in worry symptoms and a lower rate of relapse in
older adults with GAD compared to participants who continued on the SSRI medication without
CBT. For the current study, we utilized a subset of the Wetherell and colleagues (2013) dataset
and examined the effects of CBT augmentation on peak cortisol levels in older adults diagnosed
with GAD. We hypothesized that the individuals who received CBT in addition to escitalopram
would show greater decreases in peak cortisol levels compared to the participants who continued
on escitalopram without CBT.
Methods
Study participants
The sample consisted of 42 older adults who had a DSM-IV (American Psychiatric
Association, 2000) primary diagnosis of GAD. The diagnosis was determined by the Structured
Clinical Interview for DSM-IV (First, Spitzer, Gibbon, & Williams, 1995) and scoring >/= 17 on
the Hamilton Anxiety Rating Scale (Hamilton, 1959) at baseline. The study was carried out in
three locations: Pittsburgh, St. Louis, and San Diego. The study was approved by all three
institutional review boards and all participants provided informed consent. Individuals with comorbid major depression and other anxiety disorders were included in the current study so long
as GAD was the principal diagnosis. Participants were excluded if they were cognitively
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impaired (</= 25 on the Mini Mental Status Exam; Folstein, Folstein, & McHugh, 1975), had a
lifetime history of psychosis or bipolar disorder, medically unstable (e.g., severe congestive heart
failure or metastatic cancer), had current suicidal ideation, or ongoing psychotherapy. The
current study only included participants who were able to provide valid cortisol samples at both
the beginning and end of the augmentation phase. Additional information about the parent study
is reported elsewhere (Wetherell et al., 2013).
Randomization Procedure
After a 12-week phase in which participants received escitalopram 10mg daily (increased
to 20mg after 4 weeks as needed and tolerated), all participants entered an augmentation phase
lasting 16 weeks. They remained on a stable dose of escitalopram and were randomly assigned
(50:50) to receive CBT or no CBT. Briefly, the modular CBT protocol was administered by six
doctoral-level therapists, designed around each participant’s symptoms, and targeted worry and
anxiety (see Wetherell et al., 2013 for a full description). The following modules were given to
all participants: relaxation training, cognitive therapy, problem-solving skills, and
psychoeducation/ self-monitoring. A total of 70 patients (34 - CBT; 36 - no CBT) completed the
16-week randomized phase. Of those, 21 participants from the CBT group and 20 participants
from the no CBT provided valid saliva samples (see Figure 1 for a complete diagram of the
randomization process). We conducted several t-tests and chi-squares to determine if those who
provided valid saliva samples (n = 41) differed from the participants who did not have valid
saliva samples (n = 29). The results (not shown) revealed that the participants who provided
valid saliva samples did not differ on any of the background characteristics or baseline measures
compared to the participants who did not have valid saliva samples. Importantly, the change in
self-reported worry was similar across the two groups.
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Salivary sampling protocol
Participants provided three daily saliva samples while in their home - immediately upon
awakening, 30 minutes after waking, and at bedtime - for two consecutive days, both at the
beginning and end of the 16-week CBT vs. no-CBT augmentation phase. This method of
salivary collection has been shown to provide a reliable marker of adrenocortical activity in
humans (Pruessner et al., 1997). Collection was not directly supervised by researchers; the
detailed methods used in the current study to maximize adherence and accuracy of collection,
including self-report diaries and reminder calls, and of assay information, are published
elsewhere (Mantella et al., 2008). Standard procedures were used to measure cortisol in saliva
(Salimetrics, LLC, State College, PA) which have been shown to correlate highly with serum
cortisol (www.salimetrics.com). The outcome measure of interest was the peak cortisol level,
averaged over the two days of collection. We focused on peak cortisol because (1) this is when
there is maximal exposure of the glucocorticoid receptor to cortisol; and (2) our prior research
showed that peak cortisol levels are most associated with worry severity (Mantella et al., 2008)
and with cognitive function (Lenze et al., 2012).
Background Characteristics and Pre-Augmentation Measures
At the beginning of the study, participants were assessed for medical burden using the
Cumulative Illness Rating Scale for Geriatrics (CIRS-G: Miller et al., 1992) as an index of
medical comorbidity. In addition, participants were given the Penn State Worry Questionnaire
(PSWQ: Meyer, Miller, Metzger, & Borkovec, 1990) prior to the augmentation phase.
Statistical Analysis
We began by examining possible group differences in baseline demographic and clinical
characteristics, including medical comorbidity, and worry severity prior to the augmentation
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phase. We used t-tests for all continuous variables and χ2 tests for all categorical variables.
Next, we ran correlations among all of the variables of interest by treatment group status to
assess possible covariates. Lastly, we conducted a Generalized Estimating Equation (GEE)
analysis to examine the between treatment group difference in peak cortisol change over time
from pre to-post augmentation. GEE analysis is a type of regression analysis that is similar to
repeated measures ANOVA. GEEs provide a practical method to analyze correlated data arising
from repeated measures. Liang & Zeger (1986) introduced GEEs as a method of dealing with
such correlated data. The SAS procedure PROC GENMOD was used to perform GEE analysis.
Results
Descriptive Analysis
As can be seen in Table 1, the two groups did not differ significantly on any of the
background characteristics or variables of interest. It is worth noting that the PSWQ scores
between the NO CBT and CBT groups did approach significance. Thus, we conducted a posthoc
analysis to examine the change from baseline to pre-augmentation to determine if there was a
difference in response to the escitalopram treatment. The results indicated that the NO CBT
group started the true baseline (M = 58.0; SD = 9.6) higher on the PSWQ compared to the CBT
group (M = 51.3; SD = 11.0). Importantly, both groups showed comparable declines on the
PSWQ while on escitalopram prior to the augmentation phase (-4.7 and -4.5, respectively). This
would suggest there was a comparable response to the escitalopram treatment across the groups.
Correlations Among All Variables and Cortisol Change
There were no statistically significant relationships among the variables of interest in the
CBT group (see Table 2). On the other hand, there was one statistically significant relationship
in the No CBT group- higher scores on the CIRS-G were related to higher PSWQ scores. Based
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on this finding and, although not significant, the descriptive finding that the No CBT group had
higher scores on the CIRS-G (see Table 1), the final GEE model predicted the time by CBT
group interaction covarying for CIRS-G.
Effects of CBT Augmentation on Peak Cortisol Level Changes
A Generalized Estimating Equation (GEE) analysis was conducted to examine the
between treatment group difference in peak cortisol change over time from pre to postaugmentation. The results of the GEE analysis revealed that medical comorbidity (β = -0.002, se
= 0.005, 95% CI = -0.011 to +0.007, p = 0.6435) and group status (β = -0.172, se = 0.112, 95%
CI = -0.392 to +0.048, p = 0.1258) were not statistically significant predictors of peak cortisol
levels. On the other hand, there was a statistically significant effect of time (β = 0.090, se =
0.038, 95% CI = -0.165 to -0.016, p = 0.0174) indicating that there was an overall decrease in
peak cortisol levels. Most importantly, there was a statistically significant interaction between
time and group status (β = 0.137, se = 0.068, 95% CI = +0.003 to +0.271, p = 0.0445; see Figure
2). The interaction was characterized by a slight increase in peak cortisol levels for the group
that did not receive CBT; in contrast, peak cortisol levels significantly decreased in the group
that received CBT.
Based on the information reported by Mantella and colleagues (2008), it appears that the
No CBT group had peak cortisol levels slightly below a group of untreated late-life GAD
participants (see dashed line in Figure 2). Moreover, it appears that the CBT group had peak
cortisol levels significantly below the untreated GAD group but the peak cortisol levels were still
above the nonanxious older adult comparison group (see solid line in Figure 2).
We conducted a post hoc analysis to determine if the changes in peak cortisol within each
group were related, ultimately, to changes in self-reported worry. We examined the bivariate
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relationship between peak cortisol change and worry change within each group. The results
revealed that the two outcomes were not related in either group [CBT group – r(18) = -0.339, p =
0.144; No CBT group- r(17) = 0.336, p = 0.160].
Discussion
A treatment strategy of augmenting SSRI medication with CBT reduced peak salivary
cortisol in older adults with Generalized Anxiety Disorder, relative to SSRI medication alone.
This is the first study to demonstrate a physiological benefit using CBT augmentation of SSRI in
older adults with GAD. These findings are important because they demonstrate that there may
be a physiological, as well as psychological, benefit for older adults with GAD to receive
combined treatments.
The diagnosis of GAD is related to a multitude of poor cognitive (Butters et al., 2011;
Mantella et al., 2007; Rosnick et al., 2013) and health outcomes (e.g., Ansseau et al, 2005;
Romera et al., 2010) including elevated cortisol levels (Mantella et al., 2008). Cortisol-reduction
strategies may be one pathway to reducing accelerated cognitive and health-related burdens of
stress and the aging process. The current findings have demonstrated one way of doing this via
CBT augmentation of SSRIs for late-life GAD. Further, the current findings are in line with the
research demonstrating the beneficial effects of CBT for younger individuals with GAD (Tafet et
al., 2005) and extend them to older adults in the context of augmentation of SSRI, a common
indication for CBT, as antidepressant monotherapy typically yields partial response.
One possible explanation for the current findings is that the participants who received
CBT may have been able to exert more control and/or developed better coping strategies
(Abelson, Khan, Liberzon, Erickson, & Young, 2008; Tafet et al., 2005), thereby reducing peak
cortisol levels. Abelson and colleagues (2005, 2008) found that young adult and middle-aged
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patients with panic disorder and healthy participants who were made to feel more in control
and/or given access to coping mechanisms with a physiologically arousing injection had
significantly lower cortisol levels compared to individuals with access to neither. Further, the
participants in the current study who did not receive the CBT augmentation began the study and
pre-augmentation phase with higher levels of worry compared to the participants in the CBT
group. It is possible the participants in the NO CBT group had more persistent (and possibly
pernicious) anxiety thereby demonstrating the slight increase in cortisol. In support of this idea,
Dierckx and colleagues (2012) found a dose response effect of treatment status (early responder,
late responder, and non-response) and cortisol changes in a sample of children and adolescents in
which those who were anxious longer exhibited larger cortisol changes (see also Sunderland,
Wong, Hilvert-Bruce, & Andrews, 2012).
In addition, Wetherell and colleagues (2013) recently revealed that CBT augmentation to
escitalopram treatment reduced pathological worry and others (Donegan & Dugas, 2012) have
reported that changes in worry were related to changes in somatic anxiety. So, it is possible that
the reduction in worry is responsible for the decreases in cortisol that we found in the current
study. However, based on our post hoc analysis, it appears that the reductions in worry and
cortisol with CBT augmentation are not related to each other. Although others have reported a
relationship between worry severity and cortisol levels (Chaudieu et al., 2008; Mantella et al.,
2008), the findings from the post hoc analysis are consistent with literature suggesting there is no
relationship between self-reported stress and cortisol levels (e.g., Kirschbaum, Klauer, Filipp. &
Hellhammer, 1995) or other biomarkers of stress such as alpha amylase (e.g., Nater, Rohleder,
Scholtz, Ehlert, & Kirschbaum, 2007) in healthy samples. Further, Campbell and Ehlert (2012)
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reported that only approximately 25% of the studies in their review found a relationship between
salivary cortisol and subjective stress.
There are several possible public health implications of the current findings. We recently
showed that cortisol levels in older adults with GAD were negatively related to cognitive
functioning (Rosnick et al., 2013), and others (Caudle et al., 2007) have reported that older adults
with GAD who commit more cognitive errors are more likely to have poor treatment outcomes.
These findings would suggest that we could potentially improve therapeutic outcomes and
cognitive functioning by lowering cortisol levels in older adults with GAD. This idea has been
supported by Lenze and colleagues (2012), who found that cortisol reduction after escitalopram
treatment was related to memory improvements. Similarly, Mohlman (2013) reported that
participants whose executive skills increased after CBT demonstrated the best response to
treatment as indicated by significant worry reduction (see also Mohlman & Gorman, 2005).
Future research should determine if there is any added cognitive or other health benefit of
combined therapy above individual therapies.
Limitations
First, we do not know what the participants’ cortisol levels were prior to starting the
escitalopram treatment that they received for 12 weeks before randomization to CBT vs. no
CBT. Therefore, we cannot determine the level of cortisol reduction from baseline (i.e., how
much did cortisol levels decrease - if any – simply from the escitalopram treatment). Second,
due to the small sample size, the current lack of a relationship between changes in cortisol and
changes in worry should be interpreted with caution, although it is buttressed by similar findings
in healthy adults (see Campbell & Ehlert, 2012 for review; Kirschbaum et al., 1995). Future
research should examine this question with a larger sample. This would allow more intricate
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analyses as to the mechanism for the decrease (or increase in the No CBT group) in cortisol
levels for the group who received CBT augmentation. Third, this was a single pre-post design
which did not allow us to examine the long-term effects on cortisol levels for the combined
treatment. In other words, what happens to cortisol levels when the patients discontinue CBT?
If they continue CBT, will cortisol levels continue to decrease to the level of non-GAD older
adults? In addition, including multiple measurement points after treatment would allow future
researchers to better assess the relationship between cortisol and worry change. It is possible that
the long-term association between these two variables is very different than the short-term
effects that were assessed here (for more information on acute vs. long term effects of combined
therapies for anxiety disorders see Würz & Sungur, 2009). Fourth, we do not know if cortisol
reduction is a good thing and we did not have a psychotherapy or CBT only control group.
Lastly, we did not collect other physiological measures such as alpha amylase. Since a
relationship has been demonstrated between other biomarkers of stress (e.g., salivary alpha
amylase: Fisher & Newman, 2013; nesfatin-1: Gunay, Tutuncu, Aydin, Dag, & Abasli, 2012)
and GAD in college students, future research should examine if there are similar beneficial
effects of combined therapies on these markers.
Conclusions
Previous research has highlighted the individual -- and somewhat limited -- benefits of
pharmacotherapy and CBT for older adults with GAD. Combination strategies may therefore be
most beneficial for relieving the burden of this disorder. The current study provides support for
a physiological benefit using CBT augmentation of SSRI in older adults with GAD. If in fact
chronically high cortisol is causally influencing the range of deleterious health and cognitive
outcomes of late-life anxiety and other stress disorders, this behavioral strategy could mitigate
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these outcomes via cortisol reduction. This assertion requires proof with a direct test, as has
been done with cholesterol reduction and cardiac outcomes. Such a study would be desirable
but, given the large sample size and long-term follow-up needed, probably not feasible. Until
such a time, patients may be motivated by knowing the physiological effects of this behavioral
treatment.
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Table 1.
Comparison of Background and Clinical Characteristics of the GAD Participants Who Received
CBT Augmentation and Those Who Did Not.
NO CBT (n=21)
CBT (n=21)
Test Statistics
Mean (SD)
Mean (SD)
Age
68.71 (7.97)
71.19 (8.68) t = -0.96, df = 40, p = 0.3414
White
81%
86%
χ2 = 1.03, df = 2, p = 0.5979
Female
Baseline CIRS
PSWQ
(prior to augmentation)

76%

81%

9.95 (3.98)

8.86 (3.84)

χ2 = 0.14, df = 1, p = 0.7069
t = 0.90, df = 39, p = 0.3762

53.33 (9.97)

46.81 (12.53)

t = 1.87, df = 40, p = 0.0692

Note: CIRS- Cumulative Illness Rating Scale; PSWQ- Penn State Worry Questionnaire. Higher scores on both
measures indicate poorer health and more worry, respectively.
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Table 2.
Correlations Among Selected Variables and Cortisol Change by Group Status.
Cortisol ∆
Age
CIRS-G
PSWQ
Cortisol ∆
--0.11
0.14
0.35
Age
0.31
--0.30
-0.22
CIRS
-0.12
-0.14
---0.14
PSWQ
-0.11
-0.06
0.52*
--Note: CIRS- Cumulative Illness Rating Scale; PSWQ- Penn State Worry Questionnaire. The
correlations within the No CBT group are presented below the diagonal and the correlations within
the CBT group are presented above the diagonal; * p = 0.0193
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158 Patients screened

28

45 screened (-) for GAD
17 Screened (+) for GAD but
refused in-person assessment
10 Other exclusion

86 started on openlabel escitalopram
13 discontinued
73 completed 12+ weeks of openlabel escitalopram and eligible for
randomization
73 Patients randomized to
CBT or no CBT (plus
continued escitalopram)

36 randomized to CBT +
continued escitalopram

37 randomized to no CBT +
continued escitalopram

2 dropped out
1 not satisfied with meds
1 lost to follow-up

1 dropped out
1 not satisfied with meds
36 completed 16-week
randomized phase

34 completed 16-week
randomized phase
5 samples lost
9 not provided
1 dropped out
21 provided valid cortisol
samples
21 pre augmentation data
20 post augmentation data

8 samples lost
9 not provided
20 provided valid cortisol
samples
20 pre augmentation data
19 post augmentation data

Figure 1. Diagram for a Trial of Cognitive-Behavioral Therapy Augmentation of SSRI
Treatment in Older Adults with Generalized Anxiety Disorder
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Peak Cortisol (μg/dL)

0.55

29

No CBT Augmentation

CBT Augmentation

0.50
0.0466

0.45
0.40

-0.0903*

0.35
0.30
Pre augmentation

Post augmentation

Figure 2. Line graph showing the significant interaction between treatment group status (no
CBT vs. CBT) and time (pre-post augmentation) such that peak cortisol levels decrease
significantly in the CBT group and increase slightly in the group that did not receive CBT.
Ultimately, peak cortisol levels were reduced with combined SSRI and CBT treatment in late-life
GAD. Vertical lines represent the standard errors. The dashed horizontal line represents the
approximate average wake +30 cortisol levels of older adult GAD participants who were NOT
receiving any treatment and the solid horizontal line represents the approximate average wake
+30 cortisol levels of an older adult comparison group without GAD (taken from Mantella et al.,
2008).

